The construction of an impressive high-tech purpose-built R&D and manufacturing facility, which will be a vital hub for LGC’s The Native Antigen Company, one of the world’s leading suppliers of reagents enabling research into diagnostics and vaccines for emerging and endemic infectious diseases, has been completed at Oxford Technology Park.
Nick Roesen, COO of The Native Antigen Company, said: “The new facility provides us with the perfect opportunity to expand our operations, following the acquisition of The Native Antigen Company in July 2020 by LGC. The building has been designed to meet our exact specifications, which will enable us to work more efficiently and effectively. We are also excited about being part of a new science and technology community at Oxford Technology Park.”
To read more click here.